Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: University of Illinois at Chicago